Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’
July 23 2020 - 8:00AM
Business Wire
Noxopharm, a clinical-stage Australian oncology drug development
company listed on the ASX (ASX:NOX), has claimed a breakthrough in
the search for restoring immune function within “cold” microtumors,
converting them to so-called “hot” tumors.
The breakthrough stems from new preclinical data from two
independent research groups. The data confirms that idronoxil, the
active ingredient in the company’s immuno-oncology drug candidate,
and sphingosine-1-phosphate inhibitor, Veyonda®, activate
cancer-fighting immune cells and then enable their entry into
microtumors.
Cold tumors lack cancer-fighting T cells, regarded as a
fundamental hurdle in enabling immuno-oncology drugs known as
immune checkpoint inhibitors (ICIs) to work in more patients and in
more cancer types. ICIs have been hailed as the future of cancer
therapy, but they require the presence of active T cells in order
to work, meaning that they are poorly effective in cold tumors. The
majority of human tumors appear to be cold, making the development
of a drug or technique that repopulates tumors with immunocompetent
T cells a major priority of global pharmaceutical companies.
This new research was conducted by The Institute of
Biochemistry, Faculty of Medicine of the Goethe-University,
Frankfurt, and the Department of Clinical Oncology and the Centre
for Cancer Research at Hong Kong University. Other preclinical and
clinical data held by Noxopharm, together with the new research
data, leads Noxopharm to believe it is close to claiming the first
drug capable of converting tumors from cold to hot across multiple
cancer types in a well-tolerated way.
Dr. Graham Kelly, Noxopharm CEO, said, “This is exciting news
because it suggests that Veyonda could hold the answer to arguably
the biggest challenge currently facing the oncology world, that of
restoring the cancer-fighting ability of the body’s immune system
in order to achieve higher response rates to immuno-oncology
drugs.”
Noxopharm now is in a position to discuss with industry partners
the opportunity to use Veyonda to enable ICI drugs to work in
patients whose cancers fail to respond to the ICI drug alone.
About Noxopharm
Noxopharm is a clinical-stage Australian oncology drug
development company with offices in Sydney and New York. The
company has a primary focus on the development of Veyonda® and is
the major shareholder in the non-oncology drug development company,
Nyrada Inc. (ASX:NYR)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200723005149/en/
Jane Byram SCORR Marketing 512-626-2758
jane@scorrmarketing.com
Noxopharm (ASX:NOX)
Historical Stock Chart
From Jan 2025 to Feb 2025
Noxopharm (ASX:NOX)
Historical Stock Chart
From Feb 2024 to Feb 2025
